USANA Health Sciences (NYSE:USNA - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.350-3.000 for the period, compared to the consensus earnings per share estimate of 2.870. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $934.5 million.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. DA Davidson cut their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. Finally, Sidoti cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.
View Our Latest Research Report on USANA Health Sciences
USANA Health Sciences Trading Up 3.2 %
USANA Health Sciences stock traded up $0.91 during midday trading on Friday, hitting $29.55. 299,854 shares of the stock were exchanged, compared to its average volume of 166,624. USANA Health Sciences has a fifty-two week low of $27.71 and a fifty-two week high of $50.32. The stock has a market capitalization of $563.22 million, a price-to-earnings ratio of 10.44, a PEG ratio of 0.93 and a beta of 0.87. The stock's 50-day simple moving average is $33.50 and its 200 day simple moving average is $36.56.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $213.61 million during the quarter, compared to analysts' expectations of $208.82 million. Equities analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current fiscal year.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
